Beunen Kaat, Van den Abbeele Frederik, Van Crombrugge Paul, Verhaeghe Johan, Vandeginste Sofie, Verlaenen Hilde, Maes Toon, Dufraimont Els, Roggen Nele, De Block Christophe, Jacquemyn Yves, Mekahli Farah, De Clippel Katrien, Van den Bruel Annick, Loccufier Anne, Laenen Annouschka, Devlieger Roland, Mathieu Chantal, Benhalima Katrien
Department of Endocrinology, UZ Leuven, KU Leuven, Herestraat 49, Leuven, 3000, Belgium.
Medicine, KU Leuven, Herestraat 49, Leuven, 3000, Belgium.
Acta Diabetol. 2025 Jan;62(1):35-48. doi: 10.1007/s00592-024-02330-0. Epub 2024 Jul 20.
To monitor fetal size and identify predictors for birthweight in women with gestational diabetes (GDM) and normal glucose tolerance (NGT).
Cohort study of 1843 women universally screened for GDM, with routine ultrasounds each trimester. Women with GDM and NGT were categorized in subgroups by birthweight centile.
Of the total cohort, 231 (12.5%) women were diagnosed with GDM. Fetal size, incidence of large-for-gestational age (LGA: 12.3% of GDM vs. 12.9% of NGT, p = 0.822) and small-for-gestational age (SGA) neonates (4.8% of GDM vs. 5.1% of NGT, p = 0.886) were similar between GDM and NGT. GDM women with LGA neonates were more insulin resistant at baseline and had more often estimated fetal weight (EFW) ≥ P90 on the 28-33 weeks ultrasound (p = 0.033) than those with AGA (appropriate-for-gestational age) neonates. Compared to NGT women with AGA neonates, those with LGA neonates were more often obese and multiparous, had higher fasting glycemia, a worse lipid profile, and higher insulin resistance between 24 -28 weeks, with more often excessive gestational weight gain. On the 28-33 weeks ultrasound, abdominal circumference ≥ P95 had a high positive predictive value for LGA neonates in GDM (100%), whereas, in both GDM and NGT, EFW ≥ P90 and ≤ P10 had a high negative predictive value for LGA and SGA neonates (> 88%), respectively.
There were no differences in fetal size throughout pregnancy nor in LGA incidence between GDM and NGT women. EFW centile at 28-33 weeks correlated well with birthweight. This indicates that GDM treatment is effective and targeted ultrasound follow-up is useful. TRIAL REGISTRATION CLINICALTRIALS.GOV: NCT02036619. Registration date: January 15, 2014. https://clinicaltrials.gov/ct2/show/NCT02036619 .
监测妊娠期糖尿病(GDM)和糖耐量正常(NGT)女性的胎儿大小,并确定出生体重的预测因素。
对1843名接受GDM普遍筛查的女性进行队列研究,在每个孕晚期进行常规超声检查。将患有GDM和NGT的女性按出生体重百分位数分为亚组。
在整个队列中,231名(12.5%)女性被诊断为GDM。GDM组和NGT组的胎儿大小、大于胎龄儿(LGA:GDM组为12.3%,NGT组为12.9%,p = 0.822)和小于胎龄儿(SGA)新生儿的发生率(GDM组为4.8%,NGT组为5.1%,p = 0.886)相似。与出生体重适于胎龄(AGA)的新生儿的GDM女性相比,LGA新生儿的GDM女性在基线时胰岛素抵抗更强,在孕28 - 33周超声检查时估计胎儿体重(EFW)≥P90的情况更常见(p = 0.033)。与AGA新生儿的NGT女性相比,LGA新生儿的NGT女性更常肥胖且为经产妇,空腹血糖更高,血脂谱更差,在孕24 - 28周时胰岛素抵抗更高,孕期体重增加过多的情况更常见。在孕28 - 33周超声检查时,腹围≥P95对GDM中LGA新生儿具有较高的阳性预测价值(100%),而在GDM和NGT中,EFW≥P90和≤P10分别对LGA和SGA新生儿具有较高的阴性预测价值(> 88%)。
GDM和NGT女性在整个孕期的胎儿大小及LGA发生率均无差异。孕28 - 33周时的EFW百分位数与出生体重密切相关。这表明GDM治疗有效,针对性的超声随访有用。试验注册:CLINICALTRIALS.GOV:NCT02036619。注册日期:2014年1月15日。https://clinicaltrials.gov/ct2/show/NCT02036619 。